Joe Bress is a Principal at The Carlyle Group focused on private equity opportunities in the healthcare sector. He is based in New York.
Since joining Carlyle in 2007, Mr. Bress has been involved in investing/managing over $4 billion of equity investments into health care companies globally. He currently sits on the Board of Directors of WellDyneRx, Albany Molecular Research, Visionary RCM, Millicent Pharma, and the entity controlling Carlyle’s investments in X-Chem and X-Rx. He is also involved in Carlyle’s investments in PPDI, Rede D’Or Sao Luiz, and HCR ManorCare and was previously involved in Carlyle’s realized investments in MultiPlan and MedPointe. Prior to Carlyle, Mr. Bress worked in the Mergers & Acquisitions group at UBS.
He received an M.B.A. from Stanford University’s Graduate School of Business and an A.B. from Harvard College, where he graduated Magna Cum Laude.